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ABSTRACT
We wanted to define allergen-specific antibodies that
change due to specific immunotherapy. We conducted
a study with grass pollen-allergic patients and com-
pared allergen-specific IgE and IgG4 before and 
5 months after the onset of immunotherapy. Twenty-
seven patients were treated with a mixture of two grass
species: Phleum pratense and Dactilis glomerata. Sera
of patients were tested for IgE and IgG4 against four
recombinant allergens (RA): rPhl p 1, 2, 5 and rBet v 2.
Specific IgE and IgG4 to timothy and olive pollen were
also evaluated. No change in total and specific IgE
levels to RA was seen, except to rPhl p 5. We found a
decrease in specific IgE levels to olive after immuno-
therapy. Ten of 10 patients with specific IgE against a
single recombinant allergen or two RA showed the
same pattern of sensitization before and after 5 months
of immunotherapy and the administration of 4000 U/mL
allergen extract. Interestingly, we found a significant
increase in specific IgG4 to rBet v 2 and olive after
grass immunotherapy. These results indicate that appli-
cation of two grass species in immunotherapy may be
sufficient to induce an IgE and IgG4 response to RA,
grass and olive extracts. The observations in the
present study indicate that monitoring of antibodies
against RA is necessary to evaluate patients’ pattern of
sensitization and emphasize the need of component-
resolved immunotherapy.
Key words: grass pollen allergy, IgE, IgG4, immuno-
therapy, olive pollen, recombinant allergens.
INTRODUCTION
In atopic individuals, persistent exposure to allergens,
through either natural exposure or immunotherapy, leads
to synthesis of both allergen-specific IgE and IgG4 anti-
bodies.1–3 The proposed practice parameters for allergen
immunotherapy,4 established by representatives from
both the American Academy of Allergy, Asthma and
Immunology and the American College of Allergy,
Asthma and Immunology, do state that omission of clini-
cally relevant allergens from therapeutic mixtures may
decrease the effectiveness of immunotherapy, suggesting
a more inclusive approach to the treatment of grass
pollen allergy. The rationale behind this approach is to
cover the spectrum of grass pollen allergens as com-
pletely as possible. Previous studies2 have indicated that
the grass pollens elicit a complex array of antibody speci-
ficities in atopics and that the profile of antibodies specific
to the pollen extract and pure allergens differs, suggest-
ing that single grass allergen may be inadequate for
replacing grass pollen extracts for immunotherapy. How-
ever, it was only recently that Van Ree et al.5 and Ball 
et al.6 showed that allergen extract administered with an
adjuvant may induce immune reactions against extract
components not recognized before treatment.
Moreover, it was previously demonstrated that applica-
tion of just one grass species in immunotherapy may be
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Table 1 Demographic and serological characterization of individuals allergic to grass pollen before (November) and after (April)
immunotherapy
Patient Demographic data Total Specific IgE Specific IgG4 ECP
no. Sex Age Allergies Symptoms IgE Timothy rPhl p1 rPhl p2 rPhl p5 rBetv2 Olive tree Timothy rPhl p1 rPhl p2 rPhl p5 rBetv2 Olive tree (µg/mL)
(years) (kU/L) (kUA/L) (kUA/L) (kUA/L) (kUA/L) (kUA/L) (kUA/L) (mg/L) (mg/L) (mg/L) (mg/L) (mg/L) (mg/L)
1 F 50 g6, t9, w6, r, c, as
w9, t3, d1
Before 225 >100 14.5 <0.35 73 <0.35 4.22 1.4 0.22 <0.15 0.65 <0.15 0.56 10.3
After 280 >100 31.3 <0.35>100 <0.35 4.17 12.5 1.73 <0.15 3.88 0.25 1.84 9.5
2 F 27 g6, t9, t3, r, c, as
k82, w21
Before 1365 >100 78.2 45.6 72 16.2 23.2 2.78 1.12 0.88 0.66 0.23 0.47 4.7
After 1267 >100 >100 65.1>100 14.7 20.3 17.7 4.43 3.72 4.34 1.3 3.09 8
3 F 29 g6, k82, t3, r, c, as
t9, w21
Before 249 >100 63.1 6.31 42.2 3.94 12.9 0.66 0.2 <0.15 0.3 0.2 0.21 9.4
After 299 >100 55.9 9.14 71.9 4.54 16.8 13.1 1.87 0.79 4.39 0.49 1.77 21.9
4 F 16 g6, d1, t3, r, c, as
t9
Before 113 23.5 3.56 1.8 13.9 <0.35 1.96 1.29 <0.15 <0.15 0.46 <0.15 0.26 16.9
After 110 20.4 2.28 1.2 8.86 <0.35 1.16 0.73 <0.15 <0.15 <0.15 <0.15 <0.15 8.92
5 M 27 g6, t9, w6, r, c, as
w9
Before 122 52.7 18.3 <0.35 18.1 <0.35 4.08 0.38 <0.15 <0.15 <0.15 <0.15 <0.15 7.66
After 117 45.5 17.7 <0.35 16 <0.35 2.03 8.01 1.36 0.23 2.67 <0.15 1.28 4.98
6 M 30 g6, k82, t9, r, c
t3, w21, w6, 
w9
Before 52 21.4 22.5 <0.35 0.54 2 2.5 0.55 0.24 <0.15 <0.15 <0.15 0.21 9.35
After 90 14.5 15.3 <0.35 0.5 1.94 2.06 4.53 0.83 <0.15 1.05 <0.15 0.28 7.62
7 F 16 g6, t3, t9, r, c, as
w6, w9, w21
Before 119 59.3 14.4 4.97 29.9 1.66 3.5 0.24 <0.15 <0.15 <0.15 <0.15 <0.15 5.6
After 157 63.5 15.1 6.49 33.8 2.67 3.11 4.26 1.1 0.33 1.45 <0.15 0.24 2.5
8 M 10 g6, d1, k82, r, c, as
t3, t9, w21, 
w6, w9
Before 676 >100 30.2 7.48 70.2 12.3 19.6 1.42 0.35 <0.15 0.32 0.22 0.3 14.1
After 664 >100 32.4 8.56 89.7 12.1 14.6 7.81 0.91 1.45 2.9 0.45 1.14 14.3
9 M 17 w6, g6, t9 r, c, as
Before 369 43.7 4.29 8.26 10.3 <0.35 5.77 0.81 <0.15 <0.15 <0.15 <0.15 0.88 28.1
After 294 42.8 3.48 8.49 9.74 <0.35 3.65 6.46 0.61 1.52 0.54 <0.15 1.02 58.7
10 F 24 w9, g6, d1, r, c, as
t9
Before 322 16 4.08 1.03 7.3 0.7 1.74 9.26 0.7 < 0.15 3.19 1.44 1.99 6.7
After 307 13.6 3.69 1.19 7.06 0.59 1.03 10.9 0.86 < 0.15 3.77 2.63 2.55 5
11 M 16 w9, w6, t3, r, c, as
g6, d1, k82, 
t9, w21
Before 884 >100 76.6 25.9> 100 2.78 22.3 0.51 < 0.15 < 0.15 < 0.15 < 0.15 < 0.15 6.3
After 831 >100 71.5 24.9> 100 2.24 12.8 7.07 1.54 0.72 1.92 0.2 0.56 10.7
12 M 22 g6, t9 r, c, as
Before 823 46.6 47.5 < 0.15 5.31 < 0.35 1.28 < 0.15 < 0.15 < 0.15 < 0.15 < 0.15 < 0.15 3.67
After 863 41.7 45.8 < 0.15 5.36 < 0.35 0.89 < 0.15 2.31 0.51 1.93 0.39 0.4 6.97
13 F 8 g6, t9 r, c, as
Before 54 10.2 1.74 3.63 5.52 < 0.35 0.86 0.39 < 0.15 0.24 < 0.15 < 0.15 0.35 9.1
After 64 16.2 2.09 5.31 9.97 < 0.35 0.48 9.56 1.34 1.73 3.06 < 0.15 0.61 4.1
14 F 18 t9, w21, w6, r, c, as
g6, k82, t3
Before 1065 >100 > 100 < 0.15> 100 29.2 47.4 < 0.15 < 0.15 < 0.15 < 0.15 < 0.15 < 0.15 5.9
After 1263 >100 > 100 < 0.35> 100 24.4 30.8 0.94 < 0.15 <0.15 < 0.15 < 0.15 < 0.15 12.3
15 F 19 g6, t3, t9 r, c
Before 101 18.8 5.64 < 0.35 14.7 < 0.35 0.97 0.36 < 0.15 < 0.15 0.2 < 0.15 0.45 19.7
After 93 19.2 6.2 < 0.35 13.9 < 0.35 0.7 9.97 2.62 0.33 3.48 0.74 1.53 22.4
16 F 15 t9, w6, w21, r, c, as
g6, k82, t3
Before 791 >100 >100 43.6 86.1 4.23 15.5 0.33 < 0.15 < 0.15 < 0.15 0.45 0.22 4.77
After 2000 98.9 >100 51.7>100 4.77 < 0.35 35 5.08 2.41 5.25 1.24 1.54 2.43
sufficient to induce an IgG response that covers other rel-
evant Gramineae species as well.7 In other studies, it was
demonstrated that in a high percentage of patients aller-
gic to grass pollen, a mixture of only four recombinant
allergens (RA) accounted for more than 50% of IgE to
nine different natural grass pollen extracts8 and the
majority of grass pollen allergic patients is cosensitized to
rPhl p 1, rPhl p 2 and rPhl p 5.9 In contrast, a fraction of
patients allergic to grass pollen are lacking a specific
IgE against one to three RA (e.g. rPhl p 1+, rPhl p 2–,
rPhl p 5–). These subjects may be studied to evaluate
whether they start to mount de novo IgE as well as IgG4
responses against RA that were negative before grass
pollen immunotherapy.
In the present study we investigated a possible active
induction of new IgE and IgG specificities against RA and
other allergen extracts by grass pollen immunotherapy.
METHODS
Patients
Twenty-seven patients (eight males and 19 females; mean
age 25.2 years), who were selected from an outpatient pop-
ulation, finished the study. The demographic and serologic
characterization of these 27 patients is shown in Table 1.
Of 27 patients, 19 (70.37%) had symptoms of sea-
sonal asthma and rhinitis; eight (29.63%) suffering from
rhinitis during the pollen season.
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Table 1 Continued
Patient Demographic data Total Specific IgE Specific IgG4 ECP
no. Sex Age Allergies Symptoms IgE Timothy rPhl p1 rPhl p2 rPhl p5 rBetv2 Olive tree Timothy rPhl p1 rPhl p2 rPhl p5 rBetv2 Olive tree (µg/mL)
(years) (kU/L) (kUA/L) (kUA/L) (kUA/L) (kUA/L) (kUA/L) (kUA/L) (mg/L) (mg/L) (mg/L) (mg/L) (mg/L) (mg/L)
17 M 11 g6, d1, t9 r, c, as
Before 54 6.84 1.59 1.13 3.29 <0.35 0.46 <0.15 <0.15 <0.15 <0.15 <0.15 <0.15 16.8
After 56 5.54 1.61 1.1 3.08 <0.35 < 0.35 <0.15 <0.15 <0.15 <0.15 <0.15 <0.15 4
18 F 70 w9, g6, t9, r, c, as
Before w21 101 3.19 2.72 0.5 <0.35 <0.35 < 0.35 <0.15 0.24 <0.15 <0.15 <0.15 <0.15 7.7
After 100 6.34 6.11 0.53 <0.35 <0.35 0.76 0.75 0.51 0.54 <0.15 <0.15 0.22 6.1
19 F 48 g6, d1, t9 r, c
Before 493 12.6 11.3 < 0.35 <0.35 <0.35 2.65 1.47 <0.15 <0.15 <0.15 0.94 1.35 34.7
After 475 9.71 10.7 < 0.35 <0.35 <0.35 2.68 1.31 <0.15 <0.15 0.52 1.03 0.76 7.7
20 F 17 t9, w21, w6, r, c
w9, g6, k82, t3
Before 291 >100 25.5 29.8 66.4 9 13 8.36 1.28 <0.15 1.76 <0.15 0.83 4.1
After 377 >100 39.1 27.6 >100 8.29 10.6 1.16 <0.15 1.79 <0.15 <0.15 <0.15 4.5
21 F 43 g6, t9, w9 r, c, as
Before 206 73.3 10.8 8.34 35.8 <0.35 2.75 5.09 3.53 <0.15 <0.15 <0.15 <0.15 8.1
After 195 95.2 12.9 4.14 44.6 <0.35 1.99 3.94 1.09 <0.15 2.34 <0.15 0.57 8.6
22 F 12 t9, w21, r, c, as
w6, w9, g6, 
k82, t3
Before 137 64.6 11.6 2.85 21.3 4.09 3.21 1.82 0.27 0.58 <0.157<0.15 <0.15 6.78
After 103 44 7.82 2.54 18.3 3.31 2.46 <0.15 0.37 <0.15 <0.15 <0.15 <0.15 11
23 F 20 g6, d1 r, c
Before 38 7.7 8.56 <0.35 <0.35 <0.35 <0.35 0.25 0.25 0.96 <0.15 <0.15 <0.15 10.4
After 62 5.81 6.16 <0.35 <0.35 <0.35 <0.35 0.77 0.65 0.53 <0.15 <0.15 <0.15 3.3
24 F 22 t3, t9, w21, r, c, as
g6, d1, k82, 
w6, w9
Before 540 86.4 28.9 <0.35 52.7 2.11 7.22 <0.15 <0.15 <0.15 <0.15 <0.15 <0.15 19.2
After 755 95.5 45 <0.35 67.5 3.7 6.32 5.66 4.36 <0.15 0.41 0.59 0.51 17
25 F 27 g6, d1, t9 r
Before 123 31.1 8.37 6.18 14.3 <0.35 1.28 0.24 <0.15 <0.15 <0.15 <0.15 <0.15 3
After 201 62 17.6 12.6 35.5 <0.35 0.9 9.84 4.95 3.64 3.59 <0.15 0.64 2.1
26 M 53 g6, d1 r, c, as
Before 111 17.2 0.96 4.83 3.26 <0.35 1.5 0.46 <0.15 <0.15 <0.15 <0.15 <0.15 23.1
After 124 21 0.91 5.45 4.53 <0.35 1.01 5.91 1.24 1.05 1.04 <0.15 0.49 12.8
27 F 14 w9, g6, t9, r
w6
Before 1020 >100 85.2 41.7 91.1 <0.35 8.03 1.19 0.21 0.31 0.49 <0.15 0.22 6.43
After 950 >100 83.2 36 71.5 <0.35 4.46 <0.15 <0.15 <0.15 <0.15 <0.15 <0.15 4.32
g6, timothy pollen; t3, birch pollen; t9, olive tree; w6, mugwort; w9, plantain; w21, pellitory of the wall; d1, mites; k82, latex; ECP, eosinophil
cationic protein; r, rhinitis; c, conjunctivitis; as, asthma.
Sensitization towards grass pollen allergens was mea-
sured by the skin prick test (SPT). All patients had additional
SPT reactivities to one or more other allergen groups 
(i.e. tree, weeds, mites).
Study design
Treatment of the patients started in November 1998 and
the study was continued until April 1999. Two serum
samples were taken at the start of therapy (October/
November) and preseasonally (April) in the first year of
therapy. All patients were symptomless before and after
immunotherapy.
All patients were treated with extracts obtained from
the same company (Mix 2 grass: Dactilis glomerata
and Phleum pratense conjugated with sodium-alginate;
Conjuvac®; Stallergenes Italia, Saronno, Italy). Inform-
ation regarding the concentration of allergen molecules
in the extract in no longer available from the manufac-
turer. The induction phase was performed with once
weekly injections of a depot preparation over 10 weeks,
increasing to a maintenance treatment with 0.8 mL
extract (1000 U/mL). The maintenance dose was given
once every 3 weeks. The total dose administered to each
patient was 4000 U/mL.
CAP tests
Blood samples were collected before the beginning of
the treatment time and 5 months later. Sera were kept
frozen until the end of the study and were then tested all
together in one session for each antibody class. Total
and specific IgE to timothy, mugwort, birch, olive tree,
wall pellitory, mites, cat dander, Alternaria tenuis, Clado-
sporium herbarum, latex, rPhl p 1, rPhl p 2, rPhl p 5, rBet
v 2, rBet v 1 were detected by an ImmunoCAP kit, which
uses allergens covalently attached to a proprietary sponge,
a solid, phase allergosorbent (Pharmacia & Upjohn,
Uppsala, Sweden). Specific IgE levels were considered
positive at a level of 0.35 kUA/L or higher (≥ class 1).
Specific IgG4 to the same allergens was measured by
the Pharmacia CAP System Specific IgG4 FEIA.
Assessment of eosinophil cationic protein 
Eosinophil cationic protein (ECP) assessment was per-
formed by radioimmunoassay (Pharmacia & Upjohn)
according to the manufacturer’s instructions. The normal
range of ECP is 2.3–13.0 µg/L; total variation coeffi-
cients of the kit vary from 6.6 to 12%.
Assessment of myeloperoxidase
Myeloperoxidase (MPO) was measured in the serum by
radioimmunoassay (Pharmacia & Upjohn) according to
the manufacturer’s instructions. The normal range of
MPO is 170–470 µg/L.
Statistical analysis
Paired data were analyzed by Wilcoxon’s two-tailed test.
P< 0.05 was considered statistically significant.
RESULTS
The majority of grass pollen allergic patients (17 subjects;
63%) was cosensitized to rPhl p 1, rPhl p 2 and rPhl p 5.
Sera from seven patients (30%) reacted to rPhl p 1 and
rPhl p 5, but not rPhl p 2. Two sera (7.4%) reacted to
rPhl p 1 but not to rPhl p 2 and rPhl p 5; one serum
sample (3.7%) reacted to rPhl p 1 and rPhl p 2, but not to
rPhl p 5. No change in total IgE levels, ECP and MPO
levels was seen before and after immunotherapy (Fig. 1).
This confirms the absence of allergen exposure of treated
patients.
Similarly, no change in specific IgE levels to timothy,
rPhl p 1, rPhl p 2, rBet v 2 and rBet v 1, was found. 
In contrast, a significant (P = 0.042) rise in allergen-
specific IgE to rPhl p 5 was observed after treatment. 
A significant (P = 0.003) reduction in specific IgE to
olive pollen due the treatment was found (Fig. 2).
Interestingly, 10 of 10 patients with specific IgE to-
wards a single recombinant allergen or two RA showed
the same patterns of sensitization before and after
immunotherapy (Table 1). We did not find significant
variations of specific IgE to other allergens (data not
shown).
Timothy grass pollen- and olive tree pollen-specific
IgG4 directed against the four RA timothy and olive
extracts was significantly raised in treated patients com-
pared with values measured before the beginning of
immunotherapy (Fig. 3). Taken together, these results
indicate that after immunotherapy one can observe a
general increase of IgG4 antibodies against pollen extracts
and RA in grass pollen-allergic patients. Interestingly, we
found a significant increase in levels of specific IgG4 
to rBet v 2 and olive, but not to other aeroallergens (data
not shown) after immunotherapy with D. glomerata and 
P. pratense extracts.
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Fig. 1 Levels of (a) total IgE, (b) eosinophilic cationic protein (ECP) and (c) myeloperoxidase (MPO) before (November) and after
(April) short-term immunotherapy.
Fig. 2 Comparison of natural extract and recombinant allergen-specific IgE levels of treated patients obtained before (November)
and after (April) immunotherapy.
DISCUSSION
In the present study, we have shown that levels of rPhl p 1-,
rPhl p 2-, rPhl p 5- and rBet v 2-specific IgG4 rose signif-
icantly after 5 months of grass pollen immunotherapy. In
contrast, the levels of IgE against RA, except to rPhl p 5,
remained unchanged. Therefore, in partial agreement
with Gehlhar et al.,10 we did not find any influence of
immunotherapy on IgE levels. Interestingly, the patterns 
of IgE production to RA remained stable. In fact, 10
patients failed to mount IgE to RA not recognized before
therapy. This may reflect the fact that the patients were
treated for a brief period. In contrast, it may be argued
that IgE production to individual RA may be under genetic
control and, therefore, varying patterns of IgE against RA
may represent stable phenotypes that are not conditioned
by allergens administered. Van Ree et al.5 have reported
that a conversion from negative to positive was observed
in 8% of patients. This phenomenon was also observed in
sample taken > 1 year after the start of the therapy.5 It
could be argued that the appearance of IgE with speci-
ficities not detected before immunotherapy may be due to
natural exposure. In a previous study, we have docu-
mented that 127 patients with a mean time of exposure 
to grass pollen of 26.6 years were lacking specific IgE
towards particular RA. In some individuals, it is possible
that changes in specific IgE during immunotherapy are
unlikely to be a result of natural exposure.
Some studies have reported the occurence of new IgE
specificities during immunotherapy.5–11 Gehlhar et al.
reported on a grass pollen-allergic patient who had no
detectable IgE against group 5 allergens at the beginning
and whose status was still unchanged 1 year later. This
means that the application of allergens via immuno-
therapy does not necessarily lead to new sensitizations.10
Recently, Valenta demonstrated a mutual boosting effect
of pollen and latex sensitization in vivo that may be also
operative in polysensitized plant-allergic patients.12
Moreover, we cannot exclude specific IgG4 inter-
ference on specific IgE binding. Depletion for IgG
antibodies was not performed in the present study.
We found that a mixture of D. glomerata and P. pratense
extracts triggered a significant increase in specific IgG4
antibodies to rBet v 2 and to olive. This could be due to
the allergic patients’ immune system that recognized pro-
filin from Phleum.13 Van Ree et al. had previously found
that a major allergen isolated in Lolium perenne pollen
(Lol p XI) showed a high degree of homology with 
the major olive pollen allergen Ole e 1.14 Otherwise,
Daschner et al. found a correlation between specific IgE
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Fig. 3 Comparison of natural extract and recombinant allergen-specific IgG4 levels of treated patients obtained before
(November) and after (April) immunotherapy.
to profilin and specific IgE to L. perenne.15 The same
authors suggested that the sensitization with elevated
specific IgE to olive pollen is an indicator of specific IgE
to rBet v 2.15
Therefore, the appearance of IgG4 to olive not
detected before immunotherapy, as observed in the
present study, indicates that profilins are probably respon-
sible for the cross-reactivities between different biologic
sources.16–18
In a recent study, we found seasonal variation of IgE
levels to RA and natural allergens,19 as demonstrated 
in previous studies.20 This could partially explain the
observed off-season decrease in olive-specific IgE. How-
ever, the lack of reliable information about the contents
of relevant allergens in the extract used for immuno-
therapy emphasizes the need for allergen extracts with
definite molecular compositions. Moreover, IgE and IgG
responses in allergic patients may also evolve in a non-
sequential way and possess different affinities of fine
specificities. Finally, perhaps some allergens may be less
efficiently adsorbed in depot materials, resulting in vari-
able induction of IgG or downregulation of IgE.
The main implications from the results of the present
study are that: (i) 10 patients with a particular pattern of
sensitization to RA before immunotherapy maintained the
same pattern of sensitization after subcutaneous adminis-
tration of 4000 U/mL grass extracts 5 months later; and
(ii) the appearance of IgG4 with specificities not detected
before immunotherapy and directed to timothy, rPhl p 1,
rPhl p 2, rPhl p 5 and, interestingly, rBet v 2 and olive was
observed after immunotherapy.
In conclusion, given that induction of IgE antibodies
against new allergens in patients under immunotherapy
was reported,5,6 innovative forms of component-resolved
immunotherapy18–21 will be welcome.
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